临床荟萃 ›› 2022, Vol. 37 ›› Issue (8): 764-768.doi: 10.3969/j.issn.1004-583X.2022.08.017
• 综述 • 上一篇
收稿日期:
2022-03-17
出版日期:
2022-08-20
发布日期:
2022-09-26
通讯作者:
高俊茶
E-mail:junchag69@163.com
Received:
2022-03-17
Online:
2022-08-20
Published:
2022-09-26
摘要:
急性胰腺炎(acute pancreatitis, AP)是一种发病机制尚不明确的疾病,多数为轻症,但仍有部分患者会发展至重症急性胰腺炎(severe acute pancreatitis, SAP),发生局部或全身并发症,影响患者生活质量,甚至危及患者生命。Presepsin是一种表达于单核/巨噬细胞的糖蛋白,研究报道Presepsin水平在AP患者中显著高于健康者,且与疾病严重程度及预后密切相关。
中图分类号:
邢婷婷, 高俊茶. Presepsin在急性胰腺炎中的研究进展[J]. 临床荟萃, 2022, 37(8): 764-768.
[1] |
Zheng Z, Ding YX, Qu YX, et al. A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management[J]. Ann Transl Med, 2021, 9(1):69.
doi: 10.21037/atm-20-4802 pmid: 33553362 |
[2] |
Iannuzzi JP, King JA, Leong JH, et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis[J]. Gastroenterology, 2021, 162(1) :122-134.
doi: 10.1053/j.gastro.2021.09.043 pmid: 34571026 |
[3] |
Pu W, Luo G, Chen T, et al. A 5-year retrospective cohort study: Epidemiology, etiology, severity, and outcomes of acute pancreatitis[J]. Pancreas, 2020, 49(9):1161-1167.
doi: 10.1097/MPA.0000000000001637 URL |
[4] | 中华医学会急诊分会, 京津冀急诊急救联盟, 北京医学会急诊分会, 等. 急性胰腺炎急诊诊断及治疗专家共识[J]. 临床肝胆病杂志, 2021, 37(5):1034-1041. |
[5] |
Sakorafas GH, Tsiotou AG. Etiology and pathogenesis of acute pancreatitis: Current concepts[J]. J Clin Gastroenterol, 2000, 30(4):343-356.
pmid: 10875461 |
[6] |
Sendler M, Algul H. Pathogenese der akuten pankreatitis [Pathogenesis of acute pancreatitis][J]. Internist (Berl), 2021, 62(10):1034-1043.
doi: 10.1007/s00108-021-01158-y pmid: 34529120 |
[7] | Lizarazo Rodríguez JI. Fisiopatología de la pancreatitis aguda pathogenesis of acute pancreatitis[J]. Revista colombiana de Gastroenterología, 2008, 23 (2):187-191. |
[8] |
Shi N, Liu T, de la Iglesia-Garcia D, et al. Duration of organ failure impacts mortality in acute pancreatitis[J]. Gut, 2020, 69(3):604-605.
doi: 10.1136/gutjnl-2019-318241 pmid: 31233394 |
[9] |
Ding L, Zhou Y X, He C, et al. Elevated CA125 levels are associated with adverse clinical outcomes in acute pancreatitis: A propensity score-matched study[J]. Pancreatology, 2020, 20(5):789-794.
doi: S1424-3903(20)30206-4 pmid: 32660761 |
[10] |
Liang Y, Zhao X, Meng F. Procalcitonin, C-reactive protein, and neutrophil ratio contribute to the diagnosis and prognosis of severe acute pancreatitis[J]. Iran J Public Health, 2019, 48(12):2177-2186.
pmid: 31993385 |
[11] |
Drăgoescu AN, Pădureanu V, Stănculescu AD, et al. Presepsin as a potential prognostic marker for sepsis according to actual practice guidelines[J]. J Pers Med, 2020, 11(1):2.
doi: 10.3390/jpm11010002 URL |
[12] |
Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome[J]. Am J Respir Crit Care Med, 2005, 171(8):850-857.
doi: 10.1164/rccm.200407-857OC URL |
[13] |
Azim A. Presepsin: A promising biomarker for sepsis[J]. Indian J Crit Care Med, 2021, 25(2):117-118.
doi: 10.5005/jp-journals-10071-23741 URL |
[14] | 杨爱龙, 陈曦, 高宏伟, 等. 脓毒症的诊断和预后评估中Presepsin的临床价值[J]. 中华检验医学杂志, 2015, 38(2):124-127. |
[15] | 张晓冬, 康健. Presepsin在临床非感染性疾病中的研究进展[J]. 中华急诊医学杂志, 2020, 29(3):429-433. |
[16] | 胡海赟, 乔蓉, 张育才, 等. 脓毒症患儿血清可溶性CD14表达变化的临床研究[J]. 中国小儿急救医学, 2009, 16(4):334-336. |
[17] | 龚小卫, 姜勇. TLR4在哺乳动物对脂多糖反应中的作用[J]. 生物化学与生物物理进展, 2001, 28(3):300-303. |
[18] | 郑文娟, 吴建新, 任晓旭, 等. 可溶性白细胞分化抗原14亚型在脓毒症中的研究进展[J]. 中国小儿急救医学, 2016, 23(12):846-851. |
[19] | Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management[J]. BMJ, 2016, 353:i1585. |
[20] | Mussap M, Noto A, Fravega M, et al. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LB-P) in neonatal sepsis: New clinical and analytical perspectives for two old biomarkers[J]. J Matern Fetal Neonatal Med, 2011, 24(sup2):12-14. |
[21] |
Shirakawa K, Naitou K, Hirose J, et al. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients[J]. Clin Chem Lab Med, 2011, 49(5):937-939.
doi: 10.1515/CCLM.2011.145 pmid: 21345045 |
[22] |
Zou Q, Wen W, Zhang X C. Presepsin as a novel sepsis biomarker[J]. World J Emerg Med, 2014, 5(1):16-19.
doi: 10.5847/wjem.j.1920-8642.2014.01.002 pmid: 25215141 |
[23] |
Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome[J]. J Infect Chemother, 2011, 17(6):764-769.
doi: 10.1007/s10156-011-0254-x pmid: 21560033 |
[24] |
Masson S, Caironi P, Spanuth E, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: Data from the albumin italian outcome sepsis trial[J]. Crit Care, 2014, 18(1):R6.
doi: 10.1186/cc13183 URL |
[25] |
Rey NJ, Bensussan A, Vita N, et al. Soluble CD14 acts as a negative regulator of human T cell activation and function[J]. Eur J Immunol, 1999, 29(1):265-276.
pmid: 9933108 |
[26] |
Ackland GL, Prowle JR. Presepsin: Solving a soluble (CD14) problem in sepsis?[J]. Intensive Care Med, 2015, 41(2):351-353.
doi: 10.1007/s00134-014-3642-8 pmid: 25608923 |
[27] |
Chenevier-Gobeaux C, Borderie D, Weiss N, et al.Presepsin (s-CD14-ST), an innate immune response marker in sepsis[J]. Clin Chim Acta, 2015, 450:97-103.
doi: 10.1016/j.cca.2015.06.026 pmid: 26164388 |
[28] |
Yaegashi Y, Shirakawa K, Sato N, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis[J]. J Infect Chemother, 2005, 11(5):234-238.
pmid: 16258819 |
[29] |
Yamaguchi T, Ohira M, Kawagoe N, et al. High Presepsin conc-entrations in bile and its marked elevation in biliary tract diseases: A retrospective analysis[J]. Clin Chim Acta, 2021, 521:278-284.
doi: 10.1016/j.cca.2021.07.025 URL |
[30] |
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis[J]. Semin Immunopathol, 2017, 39(5):517-528.
doi: 10.1007/s00281-017-0639-8 pmid: 28555385 |
[31] | Gasteiger S, Primavesi F, Werkl P, et al. The prognostic value of Presepsin for postoperative complications following pancreatic resection: A prospective study[J]. PLoS One, 2020, 15(12):e243510. |
[32] | 陈建时, 虞瑜, 黄和, 等. 血浆Presepsin水平早期评估急性胰腺炎疾病严重程度的临床价值[J]. 中华胰腺病杂志, 2020, 20(1):12-16. |
[33] | 张月凡, 胡家骏, 翟俊山. 急性胰腺炎患者血清CRP、IL-35和Pres-epsin水平变化及临床意义[J]. 中国病案, 2021, 22(4):102-106. |
[34] |
Rotar OV. Application of presepsin in diagnosis and treatment of purulentseptic complicatitions of acute necrotic pancreatitis[J]. Klin Khir, 2016(1):20-22.
pmid: 27249919 |
[35] |
Papachristou GI, Clermont G, Sharma A, et al. Risk and markers of severe acute pancreatitis[J]. Gastroenterol Clin North Am, 2007, 36(2):277-296.
doi: 10.1016/j.gtc.2007.03.003 URL |
[36] |
Fonseca SE, Guerrero-Lozano R. Acute pancreatitis and recurrent acute pancreatitis: An exploration of clinical and etiologic factors and outcomes[J]. J Pediatr (Rio J), 2019, 95(6):713-719.
doi: 10.1016/j.jped.2018.06.011 URL |
[37] | Chai X, Huang H, Feng G, et al. Baseline serum cystatin C is a potential predictor for acute kidney injury in patients with acute pancreatitis[J]. Disease markers, 2018, 2018(Pt.III):8431219. |
[38] |
Lin J, Li Z, Zheng Y, et al. Elevated presepsin levels are associated with severity and prognosis of severe acute pancreatitis[J]. Clin Lab, 2016, 62(9):1699-1708.
doi: 10.7754/Clin.Lab.2016.160134 pmid: 28164588 |
[39] |
Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: Revision of the atlanta classification and definitions by international consensus[J]. Gut, 2013, 62(1):102-111.
doi: 10.1136/gutjnl-2012-302779 pmid: 23100216 |
[40] |
Husu HL, Leppaniemi AK, Lehtonen TM, et al. Short-and long-term survival after severe acute pancreatitis: A retrospective 17years' cohort study from a single center[J]. J Crit Care, 2019, 53:81-86.
doi: 10.1016/j.jcrc.2019.06.001 URL |
[41] | 赵群都. 脂肪酶对重症胰腺炎后续感染性胰腺坏死发生的影响及预测价值分析[J]. 中国中西医结合消化杂志, 2020, 28(9):668-671. |
[42] | 龙江超, 张泽奎. Presepsin和sTREM-1对重症急性胰腺炎合并胰周感染的预测价值分析[J]. 临床急诊杂志, 2021, 22(5):325-328, 334. |
[43] | 付东, 王浩宇. 血浆降钙素原、Presepsin及D-二聚体水平与急性胰腺炎患者预后转归的关系探讨[J]. 实用医院临床杂志, 2021, 18(3):44-47. |
[44] |
Ivanusa SY, Ivanov AM, Lazutkin MV, et al. Opportunities of modern laboratory diagnostics of infectious complications of acute pancreatitis (review).][J]. Klin Lab Diagn, 2019, 64(3):145-152.
doi: 10.18821/0869-2084-2019-64-3-145-152 URL |
[45] |
Roncon-Albuquerque RJ, Moreira-Rodrigues M, Faria B, et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice[J]. Life Sci, 2008, 83(13-14):502-510.
doi: 10.1016/j.lfs.2008.07.021 pmid: 18761356 |
[46] |
Fernández-Real JM, Pérez del Pulgar S, Luche E, et al. 14 modulates inflammation-driven insulin resistance[J]. Diabetes, 2011, 60(8):2179-2186.
doi: 10.2337/db10-1210 pmid: 21700881 |
[47] | Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation[J]. Front Cell Infect Microbiol, 2013, 3:32. |
[1] | 赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29. |
[2] | 刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52. |
[3] | 崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74. |
[4] | 王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612. |
[5] | 高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515. |
[6] | 孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525. |
[7] | 于雪华, 张宁, 吴婧, 孙惠, 赵云红, 刘改芳. 血清抵抗素、丙二醛、IL-6联合检测对急性胰腺炎严重程度的预测价值[J]. 临床荟萃, 2023, 38(5): 412-416. |
[8] | 贺翔渝, 潘燕, 张小林. 血清脂蛋白相关磷脂酶A2水平与急性缺血性脑卒中病情及预后的关系[J]. 临床荟萃, 2023, 38(4): 315-318. |
[9] | 杨金强, 张仁敏. 降钙素原与血小板比值评估发热伴血小板减少综合征预后的价值[J]. 临床荟萃, 2023, 38(4): 346-351. |
[10] | 张娜, 孙越, 董晗, 赵鹏, 杨昕, 祁源, 王玲玲. SPARC表达水平与非小细胞肺癌患者预后关系的meta分析[J]. 临床荟萃, 2023, 38(11): 972-978. |
[11] | 王会新, 赵芳晴, 张馨妍, 侯晓雯. 中国人尿酸水平与急性缺血性脑卒中患者预后关系的meta分析[J]. 临床荟萃, 2022, 37(9): 785-790. |
[12] | 郭卫娜, 康宁, 李晓莎, 李玲, 高俊淑, 李娜, 王天俊. 急性胰腺炎致Wernicke-Korsakoff综合征伴乳头体萎缩1例[J]. 临床荟萃, 2022, 37(7): 644-647. |
[13] | 轩晓倩, 赵君慧, 杨小茜. 炎性指标在非小细胞肺癌患者预后中的临床意义[J]. 临床荟萃, 2022, 37(7): 663-667. |
[14] | 叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 糖皮质激素对晚期肿瘤患者免疫疗效影响的Meta分析[J]. 临床荟萃, 2022, 37(7): 591-598. |
[15] | 周彬, 曾词正, 黄宇戈, 钟娩玲, 吴家园. pSOFA评分联合C-反应蛋白、降钙素原在脓毒症患儿预后评估中的作用[J]. 临床荟萃, 2022, 37(7): 616-622. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||